Rational Advisors LLC grew its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 328.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,240 shares of the pharmaceutical company’s stock after buying an additional 50,000 shares during the period. GlaxoSmithKline makes up 1.2% of Rational Advisors LLC’s portfolio, making the stock its 6th biggest position. Rational Advisors LLC’s holdings in GlaxoSmithKline were worth $2,314,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of GSK. Field & Main Bank bought a new position in GlaxoSmithKline during the fourth quarter worth about $132,000. First Dallas Securities Inc. bought a new position in GlaxoSmithKline during the fourth quarter worth about $142,000. Wealthcare Advisory Partners LLC boosted its holdings in GlaxoSmithKline by 1,982.8% during the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after buying an additional 3,351 shares during the last quarter. Advisory Services Network LLC boosted its holdings in GlaxoSmithKline by 24.2% during the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock worth $175,000 after buying an additional 788 shares during the last quarter. Finally, Waldron LP bought a new position in GlaxoSmithKline during the third quarter worth about $203,000. Hedge funds and other institutional investors own 9.52% of the company’s stock.

GlaxoSmithKline plc (NYSE GSK) opened at $36.27 on Tuesday. GlaxoSmithKline plc has a 1-year low of $34.52 and a 1-year high of $44.53. The company has a current ratio of 0.60, a quick ratio of 0.39 and a debt-to-equity ratio of 4.09. The firm has a market capitalization of $90,462.29, a PE ratio of 45.91, a PEG ratio of 2.33 and a beta of 0.98.

GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. The business had revenue of $10.14 billion for the quarter, compared to analysts’ expectations of $9.89 billion. analysts forecast that GlaxoSmithKline plc will post 2.82 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd will be issued a dividend of $0.633 per share. This represents a $2.53 annualized dividend and a dividend yield of 6.98%. The ex-dividend date of this dividend is Thursday, February 22nd. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s payout ratio is 258.23%.

A number of equities analysts have issued reports on the company. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Wednesday, October 18th. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, October 18th. Bank of America cut GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. ValuEngine cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Finally, UBS Group restated a “buy” rating on shares of GlaxoSmithKline in a report on Monday, January 15th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $38.57.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://theolympiareport.com/2018/02/13/glaxosmithkline-plc-gsk-holdings-boosted-by-rational-advisors-llc.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.